Stage III preliminary of Oxford antibody to start in Pune one week from now Kumar Jeetendra | September 19, 2020 Pune, Sep 19 (PTI) The phase-III human clinical trial of the COVID-19 vaccine developed by Oxford University and being fabricated by the Serum Institute of India (SII) will begin at the Sassoon General Hospital in Pune next week. “The phase-III trial of”Covishield” vaccine will start in Sassoon hospital from next week. It’s likely to start …
Electronic Vaccine Intelligence Network to follow COVID-19 antibody Kumar Jeetendra | September 21, 2020 The Electronic Vaccine Intelligence Network (eVIN) system, which provides real-time information on vaccine stocks and storage temperatures across all cold chain points in the nation, has been enhanced to deal with the needs for distribution and tracking of COVID-19 vaccine, whenever it becomes available, the Rajya Sabha was informed on September 20. A national expert …
Oxford Covid-19 immunization: Serum Institute starts phase 3 of clinical preliminary Kumar Jeetendra | September 21, 2020 The phase-III or the last stage of clinical trial of the Covid-19 vaccine’Covishield’, being developed by Oxford University, also fabricated by the Serum Institute of India (SII), began today at the state-run Sassoon General Hospital in Pune, Maharashtra on Monday, a senior official said. “We have begun the phase-III trials of the vaccine candidate. We’ll …
India preliminaries for Russia’s ‘Sputnik-V’ antibody may start in next barely any weeks: Dr Reddy’s Kumar Jeetendra | September 22, 2020 Reddy’s Laboratories Ltd could start late-stage Indian clinical trials of Russia’s potential coronavirus vaccine within the next few months, an executive in the Indian drugmaker said on Tuesday. Indian trials of this Sputnik-V vaccine candidate, being developed by Russia’s sovereign wealth fund, will enroll 1,000-2,000 participants and also be conducted at multiple private and government …
AstraZeneca gets halfway invulnerability in ease EU antibody bargain Kumar Jeetendra | September 25, 2020 European authorities will pay claims over an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters. The deals reflect different approaches by two of the world’s best drugmakers for protecting themselves as a debate rages about liabilities for vaccines …
Johnson and Johnson’s COVID-19 immunization produces solid invulnerable reaction in early preliminary Kumar Jeetendra | September 26, 2020 Pharmaceutical giant Johnson & Johnson’s experimental COVID-19 vaccine has produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, in accordance with the data published on September 25. “The data demonstrate that a single dose of COVID-19 vaccine, Ad26.COV2.S, induced a powerful neutralising antibody response in nearly all participants aged …
Covid immunization: Bharat Biotech to utilize ViroVax’s adjuvant for Covaxin Kumar Jeetendra | October 5, 2020 Trials, will use adjuvant Alhydroxiquim-II to boost immune response and longer lasting immunity. The technology has been used under this licensing arrangement with US-based ViroVax. Adjuvant is used to boost the vaccine efficacy. Covaxin is an inactivated vaccine derived from a strain of SARS-CoV-2 virus, isolated in the National Institute of Virology (NIV), Pune under …
Moderna antibody preliminary temporary workers neglect to select enough minorities, inciting lull Kumar Jeetendra | October 6, 2020 Private contractors hired by Moderna Inc to recruit volunteers for its coronavirus vaccine trial failed to enrol enough Black, Latino and Native American participants to ascertain how well the vaccine works in such populations, company executives and vaccine researchers told Reuters. To compensate for the shortfall, Moderna slowed registration of its late-stage trial and educated …
Indo-Israel fast COVID-19 testing examination to fructify in ‘matter of days’: Israeli agent Kumar Jeetendra | October 9, 2020 A game-changer rapid COVID-19 testing technologies being jointly developed by India and Israel should be prepared for rollout in”a matter of days” and it’ll have the ability to give test results in less than a minute by simply requiring an individual to blow into a tube, the Israeli envoy to India has stated. Ambassador Ron …
High-dosage favipiravir ‘strong’ against COVID-19, HCQ totally incapable: Study Kumar Jeetendra | October 11, 2020 Research conducted at the KU Leuven Rega Institute in Belgium has found that the antimalarial drug hydroxychloroquine (HCQ) doesn’t limit the multiplication of the novel coronavirus. However, a very high dose of the flu drug favipiravir does have antiviral efficacy, according to their results. The researchers gave the hamsters either hydroxychloroquine or favipiravir for four …
Eli Lilly delays preliminary of antibody drug Donald Trump promoted as COVID-19 ‘cure’ over wellbeing concern Kumar Jeetendra | October 14, 2020 Eli Lilly and Co said on Tuesday the clinical trial of its COVID-19 antibody treatment similar to one taken by US President Donald Trump has been paused due to a safety concern. Trump touted the Lilly drug, along with the antibody treatment from Regeneron Pharmaceuticals Inc that he received for his COVID-19, as compared to …
Handwashing a compelling device to forestall COVID-19, different ailments: WHO Kumar Jeetendra | October 15, 2020 Ten weeks into the pandemic, handwashing with soap and other public health measures like maintaining physical distance, practising cough etiquette and wearing a mask stay the best defence against coronavirus, the World Health Organisation said Global Handwashing Day is observed on October 15 each year to increase awareness and emphasize the importance of handwashing as …
